Transient Respiratory Motion Artifact During Arterial Phase MRI With Gadoxetate Disodium: Risk Factor Analyses

Abstract

The occurrence of transient severe motion during arterial phase MRI with gadoxetate disodium is 12.9% and is poorly predicted on the basis of risk factors.

Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know

“…Our group confirmed a trend toward significance in patients with pulmonary disease for the occurrence of TSM [15]. Other studies, however, did not replicate this observation [10,13]. The results of McClellan et al indicate that patients with low baseline breathhold duration may be the most affected by gadoxetate disodiumassociated TSM [7].…”

“…One has to keep in mind that these results are biased by weight-adapted dosing of gadoxetate disodium, resulting in higher contrast doses in patients with higher BMI. None of the other groups confirmed predisposition of high BMI towards TSM [10].…”

“…Other studies, however, were not able to confirm a dose-dependent relationship of gadoxetate disodium and TSM [8,10,12]. Also, no correlation between the dose of gadoxetate disodium and the frequency of TSM can be derived when indirectly comparing results from different studies and different sites (▶ Table 2).…”

“…This assumption might explain the differences in observed frequencies of TSM. Indeed, the study sites addressing TSM used different doses of gadoxetate disodium: weight-adapted doses of 0.025 or 0.05 mmol/kg [11,13] fixed doses of 10 ml (package size) or 20 ml [6,8,10] (▶ Table 2). …”

“…Other institutions administer it with a slower injection rate of 1 ml/s to spread the contrast bolus, thereby reducing the risk of a poorly timed arterial phase [6,10,11,13,25]. Dilution of gadoxetate disodium with saline is an alternative approach to spread the contrast bolus [9].…”